Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.

Depression and antidepressant use are common in Parkinson's disease, but the benefit of selective serotonin reuptake inhibitor (SSRI) treatment in this population has not been established. The authors treated 14 Parkinson's disease patients with major depression with escitalopram in an open-label study. Although treatment was well tolerated and correlated with a significant decrease in Inventory of Depressive Symptomatology score, response and remission rates were only 21% and 14%, respectively. However, half of the subjects met Clinical Global Impression-Improvement criteria for response. In Parkinson's disease, either SSRIs may have limited antidepressant effects, or the use of existing depression diagnostic and rating instruments may be problematic.

[1]  K. Krishnan,et al.  Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. , 2004, The American journal of psychiatry.

[2]  A. Leentjens Depression in Parkinson’s Disease: Conceptual Issues and Clinical Challenges , 2004, Journal of geriatric psychiatry and neurology.

[3]  S. Beyenburg,et al.  "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. , 2004, The Journal of clinical psychiatry.

[4]  H. Marín,et al.  Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. , 2004, The Journal of neuropsychiatry and clinical neurosciences.

[5]  S. Grill,et al.  Psychiatric comorbidities in patients with Parkinson disease and psychosis , 2004, Neurology.

[6]  D. Weintraub Diagnosing and Treating Depression in Patients With Parkinson's Disease , 2004 .

[7]  A. Leentjens,et al.  SSRIs in the treatment of depression in Parkinson's disease , 2003, International journal of geriatric psychiatry.

[8]  A. Albanese Diagnostic criteria for Parkinson's disease , 2003, Neurological Sciences.

[9]  R. Roos,et al.  Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. , 2002, British journal of clinical pharmacology.

[10]  David Eidelberg,et al.  Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. , 2002, The American journal of psychiatry.

[11]  S. Chiechio,et al.  The SSRI, Citalopram, Improves Bradykinesia in Patients With Parkinson's Disease Treated with L-Dopa , 2002, Clinical neuropharmacology.

[12]  S Mazumdar,et al.  A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[13]  G. Dell''Agnello,et al.  SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study , 2001, Clinical neuropharmacology.

[14]  L. Murri,et al.  Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms , 2000, Neurology.

[15]  D. Arciniegas,et al.  The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. , 2000, Seminars in clinical neuropsychiatry.

[16]  C. Mariani,et al.  Tolerability of paroxetine in Parkinson's disease: A prospective study , 2000, Movement disorders : official journal of the Movement Disorder Society.

[17]  K. Krishnan,et al.  A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. , 2000, The Journal of clinical psychiatry.

[18]  R. Donahue,et al.  Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. , 2000, The Journal of clinical psychiatry.

[19]  C. Clary,et al.  Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. , 2000, The American journal of psychiatry.

[20]  F. J. Arranz,et al.  Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: an open multicentre study. , 1997, Journal of affective disorders.

[21]  Roger Kurlan,et al.  A survey of antidepressant drug use in Parkinson's disease , 1997, Neurology.

[22]  R. Hauser,et al.  Sertraline for the treatment of depression in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[23]  R. Leiguarda,et al.  Cognitive functions in major depression and Parkinson disease. , 1997, Archives of neurology.

[24]  M. Bromberg,et al.  A self report measure of affective lability , 1997, Journal of neurology, neurosurgery, and psychiatry.

[25]  A. Rush,et al.  The Inventory of Depressive Symptomatology (IDS): psychometric properties , 1996, Psychological Medicine.

[26]  Matthew A. Menza,et al.  Parkinson's disease and anxiety: Comorbidity with depression , 1993, Biological Psychiatry.

[27]  H. Mayberg,et al.  Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease , 1990, Annals of neurology.

[28]  A. Rush,et al.  The inventory for depressive symptomatology (IDS): Preliminary findings , 1986, Psychiatry Research.

[29]  R. Mayeux,et al.  Altered serotonin metabolism in depressed patients with Parkinson's disease , 1984, Neurology.

[30]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[31]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[32]  M. Hamilton The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[33]  R. Reitan Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[34]  S. Gershon,et al.  Dopamine and depression , 2005, Journal of Neural Transmission / General Section JNT.

[35]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[36]  P. Bech,et al.  Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial , 1998 .

[37]  M. First,et al.  Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet , 1997 .

[38]  R. R. Abidin Psychological Assessment Resources , 1995 .

[39]  H. Mayberg,et al.  Reliability, validity, and clinical correlates of apathy in Parkinson's disease. , 1992, The Journal of neuropsychiatry and clinical neurosciences.

[40]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[41]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .